Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects

European Journal of Clinical Pharmacology

Volumn 52, Issue 6, 1997, Pages 441-449

  Muller P ^a   Flesch, G ^a   De Gasparo, M ^a   Gasparini, M ^a   Howald, H ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin II; AT1 receptor antagonist; Blood pressure; Healthy volunteers; Passive tilting; Pharmacokinetics; Renin angiotensin; System; Valsartan

Indexed keywords

ANGIOTENSIN; VALSARTAN;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VOLUNTEER;

ADULT; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALF-LIFE; HEART RATE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 0030767096     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050317     Document Type: Article

References (32)

1. 1-receptor subtype. Br J Pharmacol 110: 761-771
2. Criscione L, Bradley WA, Buehlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, de Gasparo M (1995) Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 13: 230-250
3. Whitebread S, Mele M, Kamber B, de Gasparo M (1989) Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 163: 284-291
4. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251
5. Stroedter D, Zeissig T, Heath R, Federlin K (1994) Angiotensin II antagonist CGP 48933 (Valsartan)-Ergebnisse einer doppelblinden, plazebokontrollierten Multicenter-Studie. Nieren-und Hochdruck 23: 217-220
6. Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, Meilenbrock S, Sullivan J, Bodin F (1996) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safely against amlodipine. Clin Pharmacol Ther 60: 341-346
7. Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, Heath R, Bodin F (1996) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertensin: efficacy and safety compared with placebo and enalapril. J Hypertens 14: 1147-1151
8. Müller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H (1994) Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 47: 231-245
9. Morgan J, Palmisano M, Harb G, Hirschhorn W, McNulty P, Spencer S, Prasad P, Ortiz M, Lloyd P, Piraino A (1997) The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. J Clin Pharmacol Ther 61: 35-44
10. Munafo A, Christen Y, Nussberger J, Shum L, Borland RM, Lee RJ, Waeber B, Biollaz J, Brunner HR (1992) Drug concentration response relationship in normal volunteers after oral administration of DuP 753, an angiotensin II receptor antagonist. Clin Pharmacol Ther 51: 513-521
11. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PBMWM, Brunner HR (1991) Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Circulation 83: 1333-1342
12. Müller P, Flesch G, de Gasparo M, Turri M, Preiswerk G, Howald H (1993) Single- and multiple-dose phase I studies with the angiotensin II antagonist valsartan. J Hypertension 11 [Suppl 5]: S459-S460
13. Brunner LA, Powell ML, Degen P, Flesch G (1994) A semi-automated analytical method for the determination of potential antihypertensive agents (CGP 48933 and or CGP 48369) in human plasma using high-performance liquid chromatography. Lab Robot Automat 6: 171-179
14. Shah VP, Midha KK, Dighe S (1992) Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 81: 309-312
15. Flesch G, Müller P, Hell F, Degen P, Howald H, Dieterle W (1996) Absolute oral biovailability of valsartan in healthy volunteers. Eur J Drug Metabol Pharmacokinet. Special Issue, Abstract No. 163
16. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M (1993) Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally actice nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 35: 290-297
17. Neill WA (1976) Regulation of cardiac output. In: Levine HJ (ed), Clinical Cardiovascular Physiology, Grune and Stratton, London, pp 121-142
18. Sancho J, Re R, Burton J, Barger AC, Haber E (1976) The role of the renin-angiotensin-aldosterone system in cardiovascular homeostasis in normal human subjects. Circulation 53: 400-405
19. Vargas E, Lye M, Faragher EB, Goddard C, Moser B, Davies I (1986) Cardiovascular haemodynamics and the response of vasopressin, aldosterone, plasma renin activity and plasma catecholamines to head-up tilt in young and old healthy subjects. Age and Ageing 15: 17-28
20. Nakashima M, Uematsu T, Kosuge K, Kanamaru M (1992) Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42: 333-335
21. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Weber B, Brunner HR (1993) Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22: 339-347
22. Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche TP (1996) Renal effects of angiotensin II-receptor blockade and angiotensin convertase inhibition in man. Clin Sci 90: 205-213
23. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP 3174 in humans. Clin Pharmacol Ther 58: 641-649
24. Sweet CS, Bradstreet DC, Berman SR (1994) Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 7: 1035-1040
25. Marsden PA, Brenner BM, Ballermann BJ (1990) Mechanisms of angiotensin action on vascular smooth muscle, the adrenal and the kidney. In: Laragh JH, Brenner BM (eds) Hypertension. Raven, New York, pp 1247-1271
26. Harris PJ (1992) Regulation of proximal tubule function by angiotensin. Clin Exp Pharmacol Physiol 19: 213-222
27. De Gasparo M, Levens NR (1994) Pharmacology of angiotensin II receptors in the kidney. Kidney Int 46: 1486-1491
28. 2 receptor ligands CGP 42112 B and PD 123319 in the sodium-depleted rat. Eur J Pharmacol 249: 85-93
29. 2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system. Eur J Pharmacol 259: 27-36
30. Lo M, Liu KL, Lantelme P, Sassard J (1995) Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Clin Invest 95: 1394-1397
31. 1 blockade im mRen2 transgenic rats. J Cardiovasc Pharmacol 27: 476-481
32. Silverman K, Evans SM, Strain EC, Griffiths RR (1992) Withdrawal syndrome after double blind cessation of caffeine consumption. N Engl J Med 327: 1109-1114